Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Table of Contents: ERA 2025
Featured articles
Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy
ERA’s Top 10 Abstracts
Dialysis initiation is associated with high rates of polypharmacy, which do not decrease over time
NefIgArd: Nefecon leads to sustained decline in proteinuria and eGFR stabilisation
Immune checkpoint inhibitor-induced acute interstitial nephritis characterised by distinct immunophenotypes with potentially different management
Pegcetacoplan is a treatment option for patients with C3G or IC-MPGN with nephrotic-range proteinuria
Iptacopan improves mesenchymal and capillary glomerular C3 deposition in patients with C3 glomerulopathy
Ravulizumab improves long-term quality-of-life in atypical haemolytic uraemic syndrome
Lumasiran shows continued promise in infants and young children with primary hyperoxaluria type 1
Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease
Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy
Pegcetacoplan is a treatment option for adolescents with C3G or IC-MPGN
Clinical Outcomes in Transplant and Genetic Kidney Diseases
Different Alport Syndrome genotypes lead to different outcomes in terms of kidney function and mortality
Diabetes leads to negative mortality outcomes in kidney transplant patients
Emerging Pathophysiological Mechanisms and Therapeutic Targets
NPT2b could be a new therapeutic target for kidney diseases based on preclinical data
Inhibition of the cGAS/STING pathway has the potential to aid kidney recovery in chronic granulomatous disease
New Frontiers in Cardiorenal Protection: SGLT2 Inhibitors and Emerging Therapies
Acute eGFR dip following empagliflozin initiation is not associated with acute kidney injury
Sibeprenlimab is an emerging treatment option for IgA nephropathy
Finerenone plus empagliflozin as a new potential combination in patients with type 2 diabetes and chronic kidney disease
Large meta-analysis shows that empagliflozin slows kidney progression and reduces risk among patients with multiple diseases
Canagliflozin has a dose-dependent effect on cardiovascular outcomes in patients with type 2 diabetes
Late-Breaking Nephrology Studies
Survival benefit from kidney transplantation depends on the donor source
Mineral receptor antagonists are not beneficial for patients undergoing dialysis
Spironolactone is not useful in dialysis with cardiovascular risk
Factor XI inhibition is not useful for end-stage kidney disease patients receiving haemodialysis
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com